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Disputing the ethics of research: the challenge from bioethics and 
patient activism to the interpretation of the Declaration of Helsinki in 
clinical trials. 
ABSTRACT 
In this paper we argue that the consensus around normative 
standards for the ethics of research in clinical trials, strongly 
influenced by the Declaration of Helsinki, is perceived from various 
quarters as too conservative and potentially restrictive of research 
that is seen as urgent and necessary.  We examine this problem 
from the perspective of various challengers who argue for alternative 
approaches to what ought or ought not to be permitted.  Key themes 
within this analysis will examine these claims and argue they have 
implications for the interests of the research subject, research 
governance and regulation.  Using our work with TREAT-NMD, the 
neuromuscular clinical trials network, we posit that there is a place 
for advancing the discourse of moral rights and moral duties in the 
context of research especially from the perspective of patients and 
their families, and for including the politics of patient activism and 
empowerment.  At the same time we remain vigilant to the danger 
that the therapeutic misconception and other serious vulnerabilities 
for the patient population in clinical trials, are at risk of being 
overlooked. 
177 words 
BACKGROUND 
TREAT-NMD is a European Network of Excellence which was 
formed to advance diagnosis and care and develop new treatments 
for neuromuscular disease (NMDs) – genetic conditions causing 
progressive muscle wasting and often, early death.  There are over 
60 neuromuscular conditions, most of which do not have a cure or an 
effective treatment1.  The severity of these diseases is highly variable 
and TREAT-NMD has initially focussed on two of the most severe, 
Spinal Muscular Atrophy (SMA) and Duchenne Muscular Dystrophy 
(DMD).  Both are chronic, complex, rare conditions2, normally 
diagnosed in childhood, which leave people fully dependent on care.  
With the severest form of SMA babies die in their first year and 
people with DMD have foreshortened lives, typically dying in their 
twenties.  Although some studies report good quality of life among 
people with muscular dystrophy3, more often people with the 
                                                          
1
 M. Pohlschmidt & R. Meadowcroft. 2010. Muscle Disease: the impact.  Incidence and 
prevalence of neuromuscular conditions in the UK. London: Muscular Dystrophy 
Campaign: 15. 
2
 Incidence in Europe is: for SMA 1:10,000 live births; for DMD 1:3,500 live male births. 
3
 E. Longo-Araujo de Melo & M.T. Moreno-Valdes. [Evaluation of the quality of life of 
children with Duchenne's progressive muscular dystrophy]. Rev Neurol 2007; 45: 81-87, J. 
Rahbek, et al. Adult life with Duchenne Muscular Dystrophy (DMD). Observations among 
an emerging and unforeseen patient population. Neuromuscular Disorders 2005; 15: 743-
743. 
condition and their families report care burden and support issues, 
isolation, social inequality and psychological stress and depression4. 
 
INTRODUCTION 
In this paper we provide a brief outline of the foundation of 
contemporary research governance which takes as its focus the 
rights, interests and dignity of the research subject.  We identify 
some of the challenges that have been made against this research 
governance approach, which is perceived as involving restrictive and 
overly paternalistic practices.  These challenges emerge from the 
critical stances taken within bioethics, medicine and patient activism 
and we review some of the similarities and differences between 
these positions.  With a particular focus on patient activism we 
examine its origins and relevance to these contemporary debates 
and consider the ways in which the neuromuscular patient 
community has taken on the strategies of the activist approach. We 
go on to argue that some of the activist approaches are themselves 
challengeable.  We conclude with a call for greater collaboration in 
                                                          
4
 J.E. Bothwell, et al. Duchenne muscular dystrophy - Parental perceptions. Clinical 
Pediatrics 2002; 41: 105-109, F. Boyer, et al. Factors relating to carer burden for families of 
persons with muscular dystrophy. Journal of Rehabilitation Medicine 2006; 38: 309-315, 
B.A. Gagliardi. The impact of Duchenne Muscular Dystrophy on families. Orthopaedic 
Nursing 1991; 10: 41-49, B. Natterlund, et al. The illness experience of adult persons with 
muscular dystrophy. Disability and Rehabilitation 2001; 23: 788-798. 
research governance, to include patients, clinicians, scientists and 
regulators. 
 
Current phase II trials for therapies which would significantly 
ameliorate DMD are showing promise of reaching patients.  This 
promise has heightened the expectation of a “cure” and increased 
the sense of urgency for research and with it the challenge of 
reassessing the risks that research participants might be exposed to. 
 
The person whose future is foreclosed by a progressive and 
incurable disease inspires a moral claim on human endeavour, to 
find a means of treating and ideally curing them, that few would 
dispute.  The vulnerability which comes with the diagnosis of a 
chronic, progressive disease may combine with other vulnerabilities, 
such as the dependency of the child, or person with diminished 
capacity and these vulnerabilities may be used to justify a highly 
precautionary attitude to research governance5.  With an eye to the 
history of the abuses within medical research, a level of paternalism 
would initially appear to be warranted.  However, with potential life 
saving therapies for DMD now being tested in clinical trials, patients, 
                                                          
5
 Here we are drawing upon a general ethical concept of vulnerability as being open to 
wounding or harming, however there are more technical uses of the concept in the 
context of research ethics.  A more nuanced account of vulnerability is needed and we are 
conscious that judging groups as vulnerable per se is one of the presumptions of 
paternalism in the research context that patient activism is reacting against. 
 
clinicians and scientists are asking “who decides what’s best for the 
patient”? 
 
 
DISPUTING THE ETHICS OF RESEARCH 
Articles on research ethics usually recite the 20th century history of 
ethics from the Nuremburg Code and World Medical Association’s 
Declaration of Helsinki6 through Pappworth and Beecher’s exposures 
of unethical medical research7, to the present day.  It should be 
acknowledged that the present context of medical research is a long 
way from the time, context and mindset of the Nazi experimenters.  
Although some concerns remain about the application of research 
ethics to contemporary practice8 there is now a consensus around 
                                                          
6
 Allied Control Council. 1949. Trials of War Criminals Before the Nuernberg Military 
Tribunals Under Control Council Law No. 10 Washington, DC: US Government Printing 
Office: 181-182, World Medical Association. 1964. World Medical Association Declaration 
of Helsinki. Ethical Principles for Medical Research Involving Human Subjects. The World 
Medical Association, ed. 
7
 H. Beecher. Ethics of clinical research. New England Journal of Medicine 1966; 274: 1354-
1360, M.H. Pappworth. 1967. Human Guinea Pigs: Experimentation on Man. London: 
Routledge and Kegan Paul. 
8
 C. Levine. Has AIDS Changed the Ethics of Human Subjects Research? The Journal of Law, 
Medicine & Ethics 1988; 16: 167-173, D. Shalala. Protecting Research Subjects — What 
Must Be Done. New England Journal of Medicine 2000; 343: 808-810, R. Steinbrook. 
Protecting Research Subjects — The Crisis at Johns Hopkins. New England Journal of 
Medicine 2002; 346: 716-720. 
the core principles of research ethics which can be read as a sign of 
progress9. 
 
In the light of challenges from a number of groups, we consider 
whether The Declaration of Helsinki has become a reified dogma of 
research ethics, or remains an important and relevant foundation.  
Whilst there have been revisions to the original version, the 
underlying principles remain the same.  These principles presume 
the research subject is inherently vulnerable and that  researchers 
have the potential to exploit subjects in the interest of science, 
thereby justifying a degree of paternalism in research governance.  
The traditional, what we shall call Helsinki approach, assumes that 
priority ought to be given to the welfare of the research subject 
followed by respect for their personal autonomy, both of which are 
expressed through the freedom to participate or not, and the right to 
withdraw without prejudice. 
 
                                                          
9
 Council for International Organizations of Medical Sciences (CIOMS). 2002. International 
Ethical Guidelines for Biomedical Research Involving Human Subjects. 3 edn: CIOMS: 
pp.63, Council of Europe. 1997. Convention for the Protection of Human Rights and 
Dignity of the Human Being with regard to the Application of Biology and Medicine: 
Convention on Human Rights and Biomedicine. In Oviedo, 4IV1997. C.o. Europe, ed.: 
Council of Europe, World Medical Association. 2008. World Medical Association 
Declaration of Helsinki. Ethical Principles for Medical Research Involving Human Subjects. 
The World Medical Association, ed. 
Some of the critics of the Helsinki approach discussed here 
(ourselves included) accept that the moral starting point for research 
ethics has been ratcheted up to such an extent, that there is now a 
secure foundation from which to consider further refinements, 
deviations even, from the traditional Helsinki view.  The thrust of the 
critiques we consider place a particular emphasis upon personal 
autonomy, give a new account of the duty and responsibility of 
potential research subjects and play down the vulnerability of the 
research subject10.  Indeed paternalistic constraints imposed upon 
research may actually contribute to the vulnerability of the research 
participant by preserving a power difference between the researcher 
and the researched upon thus denying the so-called “vulnerable” 
their rights to autonomy11.  Moreover, paternalistic approaches are 
evident in the documents which regulate and guide research 
governance often emphasising the duties of those conducting the 
research and the vulnerability of the research subjects12.  The 
Department of Health in the UK has encouraged greater co-operation 
                                                          
10
 J. Harris. Scientific research is a moral duty. Journal of Medical Ethics 2005; 31: 242-248.  
Harris argues that the vulnerability of the research subject should not be privileged over 
and above their duty to participate, or indeed over society’s interest in research taking 
place. 
11
 D. DeBruin. Reflections on vulnerability. Bioethics Examiner 2001; 5: 1. 
12
 CIOMS, op. cit note 9 
between patients and researchers but patient groups are still 
frustrated at the lack of collaboration13.   
 
Critiques of medical paternalism and implicitly, of the conservative 
Helsinki approach, come from several quarters, starting from the 
broad critique of medicine characterised by the development of the 
sociology of medicine in the period following the 2nd World War14, 
from within Bioethics15, and from the wider spectrum of activism that 
lies between civil rights movements and health related consumer 
groups16.  Rose and Novas have characterised the latter in terms of 
the concept of biological citizenship17.  Biological citizenship 
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  H. Munn. A new pathway for the governance of health research. New Scientist 2011, J. 
Thompson, et al. Health researchers’ attitudes towards public involvement in health 
research. Health Expectations 2009; 12: 209-220, Department of Health. 2011. 
Governance arrangements for NHS Research Ethics Committees. D.o. Health, ed. London. 
14
 M. Foucault. 1973. The Birth of the Clinic. New York: Pantheon, E. Goffman. 1961. 
Asylums: Essays on the Social Situation of Mental Patients and Other Inmates. . New York: 
Doubleday, T. Parsons. 1951. The social system. New York: Free Press. 
15
 J. Harris. 1985. The Value of Life. 1 edn. London: Routledge and Keegan Paul, I. Illich. 
1976. Medical Nemesis: The expropriation of health. New York: Pantheon, R.M. Veatch. 
1981. A Theory of Medical Ethics. New York: Basic Books. 
16
 S. Epstein. The Construction of Lay Expertise - AIDS Activism and the Forging of 
Credibility in the Reform of Clinical Trials. Sci Technol Hum Values 1995; 20: 408-437, R. 
Hugman. 1994. Ageing and the care of older people in Europe. Basingstoke: Macmillan: x, 
199. 
17
 N. Rose & C. Novas. 2005. Biological Citizenship. In Global Assemblages: technology, 
politics and ethics as anthropological problems. A.O.a.S.J. Collier, ed.: Blackwell, : 439-463. 
describes the social conditions of citizenship in terms of biological 
responsibilities, with forces operating in two directions.  One direction 
is from above, in terms of the way in which authorities regard 
individual citizens and impose responsibilities on them.  The other 
direction is from below, whereby self-organised communities of 
citizens seeking a level of participation and influence in spheres of 
concern to them.  The picture is complex and it would be too easy to 
make generalisations however, there are allegiances of common 
concern across medicine, bioethics and patient activism, but also 
differences. 
 
In terms of allegiances, there is frequent expression of frustration 
from within medicine that the medical profession is prevented from 
doing what it has been sanctioned to do in relation to research18.  In 
our work we see this sense of frustration is shared by citizen activists 
within disease communities who are advocating for their right to 
participate in decisions about care, treatment and research.  The 
Academy of Medical Sciences report on research governance in the 
UK, emphasised both the rights and responsibilities of patients to 
participate in research and encouraged more extensive patient and 
public involvement in research19.  This common interest has, in some 
                                                          
18
 AMS. 2011. A new pathway for the regulation and governance of health research. 
Academy of Medical Sciences. 
19
 AMS, op. cit note 18  at 3.2 ff.  in addition, at 3.3.2  the report also notes that medical 
paternalism may also be preventing patients joining research. 
instances, led to greater collaboration between the medical 
profession and patient organisations and this is evident within the 
neuromuscular disorders community20.  With collaboration comes a 
levelling of power between patients and researchers, with the 
consequence  that some groups of patients are less vulnerable 
because they are less disadvantaged by a lack of knowledge about 
research. 
 
Though there may be an allegiance to a biomedical research agenda 
between medicine, bioethics and patient organisations, there are 
differences.  For example there is a discernable difference of 
emphasis regarding responsibility.  From some in bioethics there is 
talk of duty21,  but the significant point about a duty is that it can be a 
form of obligation that may be insisted upon by others and in that 
sense can be viewed as a reversal of the traditional Helsinki 
approach.  The traditional approach emphasises that the interests of 
                                                          
20
 F. Muntoni, et al. 149th ENMC International Workshop and 1st TREAT-NMD Workshop 
on: "planning phase i/ii clinical trials using systemically delivered antisense 
oligonucleotides in duchenne muscular dystrophy". Neuromuscul Disord 2008; 18: 268-
275. 
21
 H.M. Evans. Should patients be allowed to veto their participation in clinical research? 
Journal of Medical Ethics 2004; 30: 198-203, M.G. Hansson & M. Hakama. Ulysses 
contracts for the doctor and for the patient. Contemporary Clinical Trials 2010; 31: 202-
206, J. Harris. Scientific research is a moral duty. J Med Ethics 2005; 31: 242 - 248, J. Harris 
& S. Holm. Should we presume moral turpitude in our children? - Small children and 
consent to medical research. Theor Med Bioeth 2003; 24: 121-129. 
the research subject are above all other interests and that the 
subject’s participation is based upon both free and informed consent 
and a lack of coercion22.  There is no mention of duty as a 
consideration.  In contrast the emphasis placed by patient 
organisations is upon the right to participate in research.  Rights are 
powers that accrue to citizens and such powers impose obligations 
upon others and can be insisted upon by those whose rights they 
are. 
 
THE CHALLENGE TO HELSINKI FROM BIOETHICS 
Contemporary medical ethics regards the principle of respect for 
autonomy as foundational.  It is against this reassuring background 
that some have begun to argue that autonomy ought to be balanced 
against other important responsibilities of the citizen, such as the 
obligations of beneficence.  It has become regarded as legitimate to 
argue that the precautionary approach of Helsinki not only limits 
autonomy, but also prevents citizens from fulfilling their moral duty to 
do good by participating in beneficial medical research23.  Harris and 
Holm24 have argued that there ought to be a change in attitude, even 
with regard to children, from the highly conservative position usually 
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 WMA, op. cit. note 9. 
23
 Harris & Holm, op. cit. note 21; Hansson & Hakama, op. cit. note 21; R. Rhodes. 
Rethinking Research Ethics. Am J Bioeth 2010; 10: 19-36. 
24
 ibid. 
adopted25.  To adopt this cautious approach is to ‘presume the moral 
turpitude of children’26 rather than consider that they are burgeoning 
moral citizens who should be encouraged to do what is right.  From 
this bioethical perspective, citizenship is extended to include children 
who should be regarded as substantially wronged if they are 
prevented from fulfilling the obligations of a ‘good’ citizen. 
 
THE CHALLENGE TO HELSINKI FROM CONSUMERISM AND 
PATIENT EMPOWERMENT 
A similar claim to the idea that citizens have a moral duty to enter 
research, albeit with a different emphasis, has emerged from the 
domain of citizen activism.  Dating from around the 1960s against a 
background of civil rights there are several strands to citizen 
activism, one related to political consumerism and another to civil 
liberties.  Both are concerned more broadly with the provision and 
governance of social goods.  Health and access to health care 
became a contested subject in this era as citizens began to 
challenge the presumption that the medical professions’ power to 
work in the patients’ best interests, meant the authority to decide for 
patients27.  A presumption roundly rejected by women’s and disability 
                                                          
25
 S.D. Edwards & M.J. McNamee. Ethical concerns regarding guidelines for the conduct of 
clinical research on children. Journal of Medical Ethics 2005; 31: 351-354. 
26
 Harris & Holm, op. cit. note 21, p. 121. 
27
 D. Lupton, et al. Caveat emptor or blissful ignorance? Patients and the consumerist 
ethos. Social Science and Medicine 1991; 33: 559 -568. 
groups, which began to insist upon the right to participate in health 
care decisions made about them28.  
It is clear that consumer activism on health falls within the bounds of 
biological citizenship as described by Rose and Novas except that 
the obligations of the citizen are reconfigured as consumer rights29.  
The consumer analogy remains a good one, since in the 
contemporary context of biomedical research there has been an 
increasing recognition that there are commodities of biovalue used in 
negotiation and exchange30.  Human tissue, genetic information, and 
access to cohorts of patients have become the basis for a kind of 
commerce and at times a bargaining tool, between patients and 
professionals31. 
 
The rights discourse can thus be seen as a substantive claim for both 
negative and positive rights. Negative rights understood as freedom 
from the interference of paternalistic doctors and regulators.  Positive 
                                                          
28
 Hugman, op. cit. note 16; M.A. Rodwin. Patient Accountability and Quality of Care: 
Lessons from Medical Consumerism and the Patients' Rights, Women's Health and 
Disability Rights Movements. American Journal of Law and Medicine, Vol 20, p 147, 1994 
1994, S. Ruzek. Transforming doctor-patient relationships. J Health Serv Res Policy 2007; 
12: 181-182. 
29
  Rose and Novas, op. cit. note 17 
30
 C. Waldby. Stem cells, tissue cultures and the production of biovalue 
Health, An Interdisciplinary Journal for the Social Study of Health, Illness and Medicine 
2002; 6: 305–323. 
31
 D. Dickenson. 2008. Body Shopping. Oxford: Oneworld. 
rights understood as rights to goods and services including the right 
to be involved in research at all stages and the right to demonstrate 
one’s responsible citizenship. 
 
Throughout the 1960s and 70s and using models of civil rights 
patients came together to form organisations to advance their own 
health interests and to set the research agenda.  In clinical trials in 
particular, the HIV/AIDS activism is a powerful exemplar which, in its 
time, radically changed the trial landscape32.  HIV/AIDS activists 
resented their exclusion from debates about treatment and research 
and challenged the restrictions on access to promising drugs, merely 
because they were the subject of randomised, controlled trials.  In 
particular they thought the ‘‘paternalistic’ policies of drug regulation 
were perceived to rob patients of the right to assume the risk of 
experimental treatment’33. 
 
Thus, the vulnerability of HIV/AIDS patients was arguably a construct 
of these exclusions and activists sought to redress the balance in a 
number of ways.  First, by learning to speak the language of 
biomedicine in order to dispute with biomedicine on equal terms. 
Second, by becoming activist consumers and developing a parallel 
market, forming buyers clubs to gain access to the most promising 
                                                          
32
 Epstein, op. cit. note 16; R. Dresser. Patient Advocates in Research: New Possibilities, 
New Problems. 11 Wash U JL & Pol'y  2003: 237-248. 
33
 Epstein, op. cit. note 16, p. 146. 
therapeutic agents. Third, by effective political lobbying, questioning 
the regulation and governance of drug development.  This 
combination of rights activism, political consumerism, and expression 
of personal autonomy through collective action, is the legacy left to 
contemporary patient groups. 
 
THE CASE OF NEUROMUSCULAR DISORDERS 
This legacy can be discerned in the evolution of organisations 
representing people with neuromuscular disorders (NMDs).  Within 
the field of muscular dystrophy, patient organisations were formed as 
a reaction to the “no help, no hope” approach of physicians, termed 
therapeutic nihilism34.  From the formation of Association Francaise 
contre les Myopathies (AFM) in France in the 1960s onwards, 
patients and their families started to organise, self-educate, raise 
money and make contacts with sympathetic scientists and clinicians.  
Parents were spurred on by the shock that not only was there no 
cure, but no treatment at all and went about creating a research 
infrastructure and engaging the interest of policymakers35. 
 
                                                          
34
 P. Furlong. 2010. Advocating for Children. In Goldlab Inaugural Symposium. University of 
Colorado: Goldlab. 
35
 V. Rabeharisoa. The struggle against neuromuscular diseases in France and the 
emergence of the "partnership model" of patient organisation. Soc Sci Med 2003; 57: 
2127-2136. 
A consequence of this activism is that patients and their families 
have assured their credibility by becoming knowledgeable about their 
diseases, raising funds and developing research programmes.  To 
give an indication of scale and significance AFM, one of the biggest 
muscular dystrophy charities, funded the establishment of a centre 
for genetics research, Genethon in 1991.  In addition to making a 
major contribution to the mapping of the human genome, Genethon 
has become a leading research centre for rare genetic disease36.  
Lobbying and awareness raising about clinical trials by the HIV/AIDS 
activists of the 1980s highlighted how progress could be accelerated 
by engaging politicians, healthcare providers and the pharmaceutical 
industry37.  NMD patient organisations have been equally successful 
in these areas and a combination of self-organisation, self-education, 
lobbying, financial leverage and ability to set the research agenda, is 
characteristic of NMD activism now.  For such active patients and 
parents it is clear that there is less information asymmetry between 
them and medical professionals, than one might find with patients 
with newly acquired disease or acting without the support of a patient 
organisation. 
 
SOCIAL AND ETHICAL COMPLEXITY IN PATIENT ACTIVISM 
                                                          
36
 Genethon. 2011. Homepage. 
37
 Epstein, op. cit. note 16;  V. Rabeharisoa & M. Callon. The involvement of patients' 
associations in research. International Social Science Journal 2002; 54: 57-65. 
In developing organisations that are: major funders of research; 
effective political lobbyists; and founders of strategic alliances, 
patients and their families have demonstrated a challenge to the 
presumption of vulnerability.  At the level of the collective the patient 
organisations and “credible” individuals within them are not 
vulnerable subjects requiring protection from the potential 
exploitation of researchers.   
 
Section 6 of the Declaration of Helsinki states that, ‘In medical 
research involving human subjects, the well-being of the individual 
research subject must take precedence over all other interests’38.  
This implies that well-being is separable from all other interests.  
However, some activists in the NMD field claim their well-being may 
depend on them being able to take part in clinical trials and they 
therefore demand participation as a positive right.  From the patient 
perspective the moral duty argued for by Harris and Holm39 becomes 
a moral right.  We see this shift as significant in two ways; first, as a 
rejection of medical professionals as the arbiters of patients’ best 
interests.  Second, as an assertion of a direct link between patient 
welfare and activism, including the right to participate in research. 
 
This latter aspect can be distinguished from the argument that there 
is a moral duty to participate in medical research.  The moral duty 
                                                          
38
 WMA, op. cit. note 9. 
39
 Harris & Holm, op. cit. note 21. 
argument is a claim about how a duty to do a greater good may take 
priority over personal autonomy and welfare.  Moreover, the moral 
duty is something impersonal; it applies to everyone, and in principle 
may be imposed on others.  However, we suggest that the activists’ 
claim is radical in a different way because it claims that the right to 
participate in research is not only an assertion of autonomy, but also 
a condition of their welfare and not in conflict with it.  The latter is a 
complex point, and suggests at least that autonomy and welfare 
interests are much more closely related than other analyses have 
suggested40.  For these patients the very notion of being “active” is 
embedded within their conception of self, self-worth and autonomy.  
Thus the welfare of the individual is contingent, at least in part, upon 
the opportunities afforded to the person to act autonomously and in a 
way that affirms their value as a moral agent.  The act of participating 
in research is both for one’s own interests and in the interests of 
similar others and as such is a form of conditional altruism.  The point 
is captured well by Gordon McClurg, a businessman with DMD who 
sees no problem in patients having multiple reasons for entering a 
trial: ‘Is there an inherent conflict between, on the one hand an 
aspiration to benefit personally at as early a stage as possible from a 
treatment that may restore physical capacity, improve quality of life or 
even extend it, and on the other, the desire to be part of a clinical trial 
to establish the efficacy of an experimental treatment, a process 
                                                          
40
 R. Dworkin. 1994. Life's dominion : an argument about abortion, euthanasia, and 
individual freedom. 1st Vintage Books edn. New York: Vintage Books: xiii, 273. 
which may well advance the interests and wellbeing of other or all 
sufferers?’41.   
 
The challenge that this landscape of patient activism presents to the 
Helsinki tradition is significant.  The idea that the research subject is 
also someone who insists upon their right to participate in research, 
is an active ally of the researcher and someone who sees their 
interests as intimately bound up with the possibility that research 
happens, departs from the idea of the vulnerable and potentially 
exploitable research subject inherent in the Helsinki approach.  If we 
give credence to this new relationship between the researchers and 
the researched upon then the next question is surely, how should we 
be interpreting notions of patient interests as contained in the 
Helsinki declaration?  Whilst we are sympathetic to the need for 
revision to Helsinki and the research regulation it has inspired we are 
also concerned that it should not be abandoned completely for 
reasons we now explore. 
 
PUSHING THE RIGHTS AGENDA 
In our empirical work we have seen that a strong insistence upon the 
right to participate is not without its problems.  We can see the 
acceptability or otherwise of risks associated with research, as a 
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 S. Woods, et al. The therapeutic misconception, decision making and informed consent: 
the ethics of trial participation for neuromuscular disorders. in preparation 2011. 
territory of dispute between activists and professionals42.   For 
example, some patients with life limiting disease seem prepared to 
take risks over and above those which are deemed acceptable both 
by the medical professions, ethics committees and by wider 
society43.  There are men with DMD, nearing or beyond the mean 
age of death for their disease group, who declare they would, ‘rather 
die trying [an experimental therapy], than die from the disease 
itself’44.  These men take the idea of altruism to another level, that of 
sacrificial altruism.  A minority of patient advocates see ethical 
safeguards as a restriction on what they are permitted to do with their 
own body and that this has a negative effect on their well-being and 
limits their self-determination.  The claim is repeatedly made by 
patient activists that no-one is better placed than the person with the 
condition, or their family, to make a judgement about the level of risk 
that is worthwhile. 
 
Those prepared to act as sacrificial altruists might argue that, even if 
they personally come to harm through clinical trial participation, the 
NMD community, their biosocial group, might benefit45.  It can be 
                                                          
42
 F.G. Miller & S. Joffe. Limits to research risks. Journal of Medical Ethics 2009; 35: 445-
449.; M.P. Slevin, H; Lynch, D; Drinkwater, J; Gregory, WM;. Who should measure the 
quality of life, the doctor or the patient? British Journal of Cancer 1988; 57: 109-112. 
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 Miller & Joffee, op. cit. note 42. 
44
 P. McCormack. 2009. Notes from Action Duchenne conference. personal 
communication. 
45
 Waldby, op. cit. note 30. 
seen that in the case of chronic, progressive, disease the potential 
therapeutic benefit of taking part in a trial can weigh heavily on the 
scales for some patients and at the same time, as they lose function 
and get closer to the age at which death is expected, risk can seem 
less threatening46.  The combination of the lack of separation 
between therapy and experiment and the hope for therapeutic benefit 
for both themselves and the disease community, can lead some 
patients to develop a “nothing left to lose attitude”, which drives them 
to challenge the boundaries of what others see as acceptable risk. 
Such opinions might well be bolstered by an appeal to consumer 
autonomy,  that research ought to be a laissez faire market in which 
the only precautionary principle is that of caveat emptor.  In our view 
this would be an extreme shift.  Whilst there are legitimate reasons 
for arguing that the Helsinki approach is too paternalistic, these are 
reasons for a revision of the approach rather than wholesale 
abandonment. 
 
It should be recognised that this is not a dispute about personal 
autonomy but rather a dispute about what respect for autonomy is an 
entitlement to.  There is a clear need to take seriously the claim that 
autonomous individuals should be permitted to assert positive rights 
and make choices at some risk to themselves.  However, the 
potential for autonomous rights to fly in the face of widely sanctioned 
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concerns about, and responsibility for the welfare, safety and dignity 
of others must also be given credence.  Such responsibilities are 
shared equally and generally by patients, parents, researchers, 
clinicians, in fact all citizens.  This is not an excuse to merely dismiss 
the claims of patients but is rather a call to find a means to establish 
the extent of patient rights that ought to be sanctioned and thus 
render meaningful the moral responsibility enshrined in the 
Declaration of Helsinki ‘to protect the life, health, dignity, integrity, 
right to self-determination...’47. 
 
There is a common interest in establishing and protecting standards 
of dignity and respect which reflect the shared societal concern for all 
of its members.  The TREAT-NMD network provides a good example 
of how such a collective approach can work in practice and of the 
kinds of mechanisms that can successfully allow different groups to 
exchange ideas and explore each others’ points of view in depth.  
20% of the EC-funded partners in ANONYMOUS are patient 
organisations, 2 of them umbrella group, together representing 
almost 500 rare disease patient organisations across Europe.  The 
network is immediately mutually beneficial as it situates the patient 
organisations within a wider club of interest which includes scientists, 
clinicians and researchers, and vice versa. 
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The network uses a number of mechanisms to encourage exchange 
between the different groups.  One is appointment on committees 
and most have upwards of a third of members who are patients or 
their representatives.  These committees do regular empirical work 
together48 and the network has a general commitment to 
transparency and open debate.  One example of a practical outcome 
of this deep and close collaboration was a workshop organised by 
TREAT-NMD and the European Medicines Agency (EMA) to discuss 
how regulation might work for a potential personalised therapy for 
NMD.  The meeting discussed the usual clinical and pharmacological 
issues but began with the patient perspective and concluded with a 
presentation on ethical issues 49 
 
Recent wider recognition of the value of encouraging collaboration 
between different groups involved in clinical trials can be seen in 
EURORDIS’ Clinical Trials Charter for use between sponsors and 
patient organisations, as well as Patient Partner’s publications on 
Patient Involvement in Clinical Research50. 
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 THE CASE OF CHILDREN 
In addition to the issues already covered, when considering the 
impact of rare disease upon children, there are other and specific 
concerns.  Some parents are prepared to take decisions that put the 
family welfare at stake, through personal and financial sacrifice, in 
order to increase the chances of entering their child into research.  
So, talk of: moving to another country in the hope of accessing a 
clinical trial; issuing legal challenges to companies who do not 
release the results of drug trials as quickly as families hoped; building 
research facilities in countries with weak jurisdiction to avoid 
regulation; and buying into biotech companies to influence research 
priorities which will favour their child’s condition, are all examples of 
the type of conversations which regularly take place in the patient 
community.  Such discussions are difficult to capture as they do not 
usually take place within the public arena and are open to criticism 
from other members of the patient groups and the medical 
profession.  One public case, which illustrates the extreme 
motivations behind some actions by patients, was the Gunvalson trial 
where the mother of a boy with DMD issued a lawsuit against a 
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biotech company to argue for access to a therapy which was still in 
phase II trials51. 
 
Evident in these examples is the passion and desperation of parents 
seeking the best for their child.  Also evident are the circumstances in 
which a misleading conflation of ideas is made easy.  First, the belief 
that a clinical trial means treatment, the therapeutic misconception, 
which drives some parents to go to extreme lengths to chase a “cure” 
for their child52.  Second, driven by the therapeutic misconception, is 
the conflation between the right that research happens, a legitimate 
and reasonable expectation, and the right to participate in research, 
which, per se, is not a reasonable expectation53.  The effectiveness 
of collective action in raising awareness, and setting and resourcing 
the research agenda may play a role in fostering these confusions, 
especially if a family have been particularly involved in such 
activities.  There may be a notion that their child deserves to be 
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included in the trial in return for the family having given of their own 
resources, a point emphasised in the Gunvalson case54. 
 
CONCLUSIONS 
It is clear that solutions to the complex social and ethical issues we 
have described lie neither in fettering patient activism nor 
abandoning ethical governance.  Patient activism can be effectively 
expressed within collaborative networks as an alliance of peers, 
rather than as a reactionary force. 
 
At the same time it is necessary to be vigilant that the positive gains 
that have been made through patient activism do not become a 
springboard to therapeutic misconception and unacceptable risk 
taking.  A balanced view of the activism that pushed the boundaries 
for HIV/AIDS and other disease groups will recognise that some of 
the activism was ultimately self-defeating55.  There is still a place for 
the precepts and concerns enshrined within the Helsinki approach 
but it is legitimate to question the way in which those precepts and 
concerns are interpreted and applied.  This is a collective 
responsibility and not the sole prerogative of a professional elite.  
Patient organisations want their voices heard but they also want 
responsible, timely and ethical research into the conditions that afflict 
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them.  In the ethical governance of research there needs to be a 
balance between the science orientated, professional, approach to 
research governance and a social and emotional one, which 
recognises that having a chronic progressive disease is as great a 
threat to dignity and well-being as participation in a clinical trial has 
the potential to be. Research ethics committees and Institutional 
review boards could place greater emphasis on the issue of patient 
involvement than is currently the case56. However real collaboration 
needs to happen much further upstream from the point of ethical 
approval and will require academic researchers and pharmaceutical 
companies to be open to patient involvement from the earliest phase 
of research design.  If but one aspect of the Helsinki approach could 
change then it should be that the normative prescriptions are 
developed within a collaborative dialogue between professionals and 
patients, their families and advocates. 
 
So, working alongside researchers and clinicians and engaging with 
regulators would give patient organisations the opportunity to 
substantially determine what constitutes ethical research and would 
add legitimacy to the necessary sanctions and controls imposed by 
research governance. 
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